Pre-Congress Symposium 8
Radiopharmacy + Oncology & Theraonostics + Drug Development Committee
Monday, October 11, 14:00-17:00

Session Title
Novel Radionuclides for Theranostics on the Horizon

Chairpersons
Cristina Müller (Villingen, Switzerland)
Oliver Neels (Dresden, Germany)

Programme
14:00 - 14:20 Christophe Deroose (Leuven, Belgium): Novel Radionuclides for Theranostics - What for?
14:20 - 14:40 Thierry Stora (Geneva, Switzerland): PRISMAP - The European Medical Isotope Programme Providing Novel Radionuclides
14:40 - 15:00 Mattia Manzolaro (Rome, Italy): Mass Separation Techniques - The Way to High Quality?
15:00 - 15:20 Renata Mikolajczak (Otwock, Poland): The Technical Challenges to Provide Novel Radionuclides
15:20 - 15:35 Break
15:35 - 15:55 Cristina Müller (Zürich, Switzerland): Novel Radionuclides - Preclinical Proof of Concept
15:55 - 16:15 Dana Niculae (Bucharest, Romania): Novel Radionuclides - But in Right Quality and for the Right Target
16:15 - 16:35 Isabel Rauscher (Munich, Germany): Novel Radionuclides - What Do We Already Know in Clinical Applications?
16:35 - 16:55 Oliver Neels (Dresden, Germany): Novel Radionuclides - Don’t Forget the Regulatory Side
16:55 - 17:00 Summary by Chairperson

Educational Objectives
1. To provide an overview, which novel radionuclides and new technologies are on the horizon in particular for theraonostics
2. To provide an insight in the current status of preclinical research and the requirements for development of radiopharmaceuticals based on innovative radionuclides
3. To establish the clinical requirements, where novel radionuclides are needed and how they can become available

Summary
Recent years have seen many efforts to investigate several novel radionuclides, currently neither commercially available nor clinically used. Especially with the advent of theraonostics aims are to improve therapeutic efficacy, to adapt the physical half live to the target under investigation or to improve the “matched pair” concept, i.e. eliminating differences in chemistry between a diagnostic and therapeutic radionuclides. This pre-Congress symposium will discuss, which candidates are promising, how technical and organisational advances may lead to better availability, where are major challenges, what is clinically required and desired, where are regulatory hurdles and where we currently stand in the development. The views from the producers, preclinical radiopharmaceutical researchers and the clinician will be included to provide an up to date status.

Key Words
Radionuclides, theraonostics, accelerators, mass separation, radiopharmaceutical development